Population pharmacokinetics of olprinone in healthy male volunteers

Takayuki Kunisawa, Hidefumi Kasai, Makoto Suda, Manabu Yoshimura, Ami Sugawara, Yuki Izumi, Takafumi Iida, Atsushi Kurosawa, Hiroshi Iwasaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Olprinone decreases the cardiac preload and/or afterload because of its vasodilatory effect and increases myocardial contractility by inhibiting phosphodiesterase III. Purpose: The objective of this study was to characterize the population pharmacokinetics of olprinone after a single continuous infusion in healthy male volunteers. Methods: We used 500 plasma concentration data points collected from nine healthy male volunteers for the study. The population pharmacokinetic analysis was performed using the nonlinear mixed effect model (NONMEM®) software. Results: The time course of plasma concentration of olprinone was best described using a two-compartment model. The final pharmacokinetic parameters were total clearance (7.37 mL/minute/kg), distribution volume of the central compartment (134 mL/kg), intercompartmental clearance (7.75 mL/minute/kg), and distribution volume of the peripheral compartment (275 mL/kg). The interindividual variability in the total clearance was 12.4%, and the residual error variability (exponential and additive) were 22.2% and 0.129 (standard deviation). The final pharmacokinetic model was assessed using a bootstrap method and visual predictive check. Conclusion: We developed a population pharmacokinetic model of olprinone in healthy male adults. The bootstrap method and visual predictive check showed that this model was appropriate. Our results might be used to develop the population pharmacokinetic model in patients.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalClinical Pharmacology: Advances and Applications
Volume6
Issue number1
DOIs
Publication statusPublished - 2014 Mar 4
Externally publishedYes

Fingerprint

Healthy Volunteers
Pharmacokinetics
Population
Type 3 Cyclic Nucleotide Phosphodiesterases
olprinone
Software

Keywords

  • Men
  • Pharmacokinetic model
  • Phosphodiesterase III inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Population pharmacokinetics of olprinone in healthy male volunteers. / Kunisawa, Takayuki; Kasai, Hidefumi; Suda, Makoto; Yoshimura, Manabu; Sugawara, Ami; Izumi, Yuki; Iida, Takafumi; Kurosawa, Atsushi; Iwasaki, Hiroshi.

In: Clinical Pharmacology: Advances and Applications, Vol. 6, No. 1, 04.03.2014, p. 43-50.

Research output: Contribution to journalArticle

Kunisawa, T, Kasai, H, Suda, M, Yoshimura, M, Sugawara, A, Izumi, Y, Iida, T, Kurosawa, A & Iwasaki, H 2014, 'Population pharmacokinetics of olprinone in healthy male volunteers', Clinical Pharmacology: Advances and Applications, vol. 6, no. 1, pp. 43-50. https://doi.org/10.2147/CPAA.S50626
Kunisawa, Takayuki ; Kasai, Hidefumi ; Suda, Makoto ; Yoshimura, Manabu ; Sugawara, Ami ; Izumi, Yuki ; Iida, Takafumi ; Kurosawa, Atsushi ; Iwasaki, Hiroshi. / Population pharmacokinetics of olprinone in healthy male volunteers. In: Clinical Pharmacology: Advances and Applications. 2014 ; Vol. 6, No. 1. pp. 43-50.
@article{968c40d04e934f239830ea99bf57762c,
title = "Population pharmacokinetics of olprinone in healthy male volunteers",
abstract = "Background: Olprinone decreases the cardiac preload and/or afterload because of its vasodilatory effect and increases myocardial contractility by inhibiting phosphodiesterase III. Purpose: The objective of this study was to characterize the population pharmacokinetics of olprinone after a single continuous infusion in healthy male volunteers. Methods: We used 500 plasma concentration data points collected from nine healthy male volunteers for the study. The population pharmacokinetic analysis was performed using the nonlinear mixed effect model (NONMEM{\circledR}) software. Results: The time course of plasma concentration of olprinone was best described using a two-compartment model. The final pharmacokinetic parameters were total clearance (7.37 mL/minute/kg), distribution volume of the central compartment (134 mL/kg), intercompartmental clearance (7.75 mL/minute/kg), and distribution volume of the peripheral compartment (275 mL/kg). The interindividual variability in the total clearance was 12.4{\%}, and the residual error variability (exponential and additive) were 22.2{\%} and 0.129 (standard deviation). The final pharmacokinetic model was assessed using a bootstrap method and visual predictive check. Conclusion: We developed a population pharmacokinetic model of olprinone in healthy male adults. The bootstrap method and visual predictive check showed that this model was appropriate. Our results might be used to develop the population pharmacokinetic model in patients.",
keywords = "Men, Pharmacokinetic model, Phosphodiesterase III inhibitor",
author = "Takayuki Kunisawa and Hidefumi Kasai and Makoto Suda and Manabu Yoshimura and Ami Sugawara and Yuki Izumi and Takafumi Iida and Atsushi Kurosawa and Hiroshi Iwasaki",
year = "2014",
month = "3",
day = "4",
doi = "10.2147/CPAA.S50626",
language = "English",
volume = "6",
pages = "43--50",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Population pharmacokinetics of olprinone in healthy male volunteers

AU - Kunisawa, Takayuki

AU - Kasai, Hidefumi

AU - Suda, Makoto

AU - Yoshimura, Manabu

AU - Sugawara, Ami

AU - Izumi, Yuki

AU - Iida, Takafumi

AU - Kurosawa, Atsushi

AU - Iwasaki, Hiroshi

PY - 2014/3/4

Y1 - 2014/3/4

N2 - Background: Olprinone decreases the cardiac preload and/or afterload because of its vasodilatory effect and increases myocardial contractility by inhibiting phosphodiesterase III. Purpose: The objective of this study was to characterize the population pharmacokinetics of olprinone after a single continuous infusion in healthy male volunteers. Methods: We used 500 plasma concentration data points collected from nine healthy male volunteers for the study. The population pharmacokinetic analysis was performed using the nonlinear mixed effect model (NONMEM®) software. Results: The time course of plasma concentration of olprinone was best described using a two-compartment model. The final pharmacokinetic parameters were total clearance (7.37 mL/minute/kg), distribution volume of the central compartment (134 mL/kg), intercompartmental clearance (7.75 mL/minute/kg), and distribution volume of the peripheral compartment (275 mL/kg). The interindividual variability in the total clearance was 12.4%, and the residual error variability (exponential and additive) were 22.2% and 0.129 (standard deviation). The final pharmacokinetic model was assessed using a bootstrap method and visual predictive check. Conclusion: We developed a population pharmacokinetic model of olprinone in healthy male adults. The bootstrap method and visual predictive check showed that this model was appropriate. Our results might be used to develop the population pharmacokinetic model in patients.

AB - Background: Olprinone decreases the cardiac preload and/or afterload because of its vasodilatory effect and increases myocardial contractility by inhibiting phosphodiesterase III. Purpose: The objective of this study was to characterize the population pharmacokinetics of olprinone after a single continuous infusion in healthy male volunteers. Methods: We used 500 plasma concentration data points collected from nine healthy male volunteers for the study. The population pharmacokinetic analysis was performed using the nonlinear mixed effect model (NONMEM®) software. Results: The time course of plasma concentration of olprinone was best described using a two-compartment model. The final pharmacokinetic parameters were total clearance (7.37 mL/minute/kg), distribution volume of the central compartment (134 mL/kg), intercompartmental clearance (7.75 mL/minute/kg), and distribution volume of the peripheral compartment (275 mL/kg). The interindividual variability in the total clearance was 12.4%, and the residual error variability (exponential and additive) were 22.2% and 0.129 (standard deviation). The final pharmacokinetic model was assessed using a bootstrap method and visual predictive check. Conclusion: We developed a population pharmacokinetic model of olprinone in healthy male adults. The bootstrap method and visual predictive check showed that this model was appropriate. Our results might be used to develop the population pharmacokinetic model in patients.

KW - Men

KW - Pharmacokinetic model

KW - Phosphodiesterase III inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84895812542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895812542&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S50626

DO - 10.2147/CPAA.S50626

M3 - Article

AN - SCOPUS:84895812542

VL - 6

SP - 43

EP - 50

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

IS - 1

ER -